NASDAQ:MRKR - Nasdaq - US57055L2060 - Common Stock - Currency: USD
NASDAQ:MRKR (5/1/2025, 9:48:06 AM)
1.22
+0.03 (+2.52%)
The current stock price of MRKR is 1.22 USD. In the past month the price increased by 4.39%. In the past year, price decreased by -71.8%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.64 | 338.58B | ||
AMGN | AMGEN INC | 14.36 | 152.97B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.26B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1727.88 | 128.82B | ||
REGN | REGENERON PHARMACEUTICALS | 13.2 | 63.95B | ||
ARGX | ARGENX SE - ADR | 333.81 | 38.73B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.84B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.70B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.07B | ||
NTRA | NATERA INC | N/A | 20.35B | ||
BIIB | BIOGEN INC | 7.38 | 17.80B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.59B |
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 5 full-time employees. The company went IPO on 2016-11-08. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. The company is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). The company has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
MARKER THERAPEUTICS INC
2450 Holcombe Blvd, Suite Bcm-A, Ms: Bcm251
Houston TEXAS 77027 US
CEO: Peter Hoang
Employees: 8
Company Website: https://markertherapeutics.com/
Investor Relations: https://www.markertherapeutics.com/investors/
Phone: 17134006400
The current stock price of MRKR is 1.22 USD. The price increased by 2.52% in the last trading session.
The exchange symbol of MARKER THERAPEUTICS INC is MRKR and it is listed on the Nasdaq exchange.
MRKR stock is listed on the Nasdaq exchange.
10 analysts have analysed MRKR and the average price target is 11.09 USD. This implies a price increase of 809.22% is expected in the next year compared to the current price of 1.22. Check the MARKER THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MARKER THERAPEUTICS INC (MRKR) has a market capitalization of 13.07M USD. This makes MRKR a Nano Cap stock.
MARKER THERAPEUTICS INC (MRKR) currently has 8 employees.
MARKER THERAPEUTICS INC (MRKR) has a resistance level at 1.25. Check the full technical report for a detailed analysis of MRKR support and resistance levels.
The Revenue of MARKER THERAPEUTICS INC (MRKR) is expected to decline by -61.26% in the next year. Check the estimates tab for more information on the MRKR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MRKR does not pay a dividend.
MARKER THERAPEUTICS INC (MRKR) will report earnings on 2025-05-13.
MARKER THERAPEUTICS INC (MRKR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.2).
The outstanding short interest for MARKER THERAPEUTICS INC (MRKR) is 2.04% of its float. Check the ownership tab for more information on the MRKR short interest.
ChartMill assigns a technical rating of 1 / 10 to MRKR. When comparing the yearly performance of all stocks, MRKR is a bad performer in the overall market: 94.43% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to MRKR. The financial health of MRKR is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months MRKR reported a non-GAAP Earnings per Share(EPS) of -1.2. The EPS decreased by -28.38% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -48.73% | ||
ROE | -57.82% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to MRKR. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -123.21% and a revenue growth -61.26% for MRKR